The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Acorda Therapeutics Inc | COM | 00484M106 | 2,057 | 154,806 | SH | SOLE | 154,806 | 0 | 0 | ||
| Allergan PLC | SHS | G0177J108 | 2,006 | 13,700 | SH | SOLE | 13,700 | 0 | 0 | ||
| Amarin Corp PLC | SPONS ADR NEW | 023111206 | 3,087 | 148,695 | SH | SOLE | 148,695 | 0 | 0 | ||
| Bausch Health Cos Inc | COM | 071734107 | 5,080 | 205,660 | SH | SOLE | 205,660 | 0 | 0 | ||
| BioMarin Pharmaceutical Inc | COM | 09061G101 | 733 | 8,250 | SH | SOLE | 8,250 | 0 | 0 | ||
| Audentes Therapeutics Inc | COM | 05070R104 | 9,779 | 250,620 | SH | SOLE | 250,620 | 0 | 0 | ||
| Cymabay Therapeutics Inc | COM | 23257D103 | 2,792 | 210,257 | SH | SOLE | 210,257 | 0 | 0 | ||
| Chiasma Inc | COM | 16706W102 | 1,061 | 203,948 | SH | SOLE | 203,948 | 0 | 0 | ||
| Deciphera Pharmaceuticals Inc | COM | 24344T101 | 995 | 42,865 | SH | SOLE | 42,865 | 0 | 0 | ||
| Exelixis Inc | COM | 30161Q104 | 2,150 | 90,356 | SH | SOLE | 90,356 | 0 | 0 | ||
| Global Blood Therapeutics Inc | COM | 37890U108 | 4,610 | 87,099 | SH | SOLE | 87,099 | 0 | 0 | ||
| Heron Therapeutics Inc | COM | 427746102 | 9,498 | 388,623 | SH | SOLE | 388,623 | 0 | 0 | ||
| Intercept Pharmaceuticals Inc | COM | 45845P108 | 1,337 | 11,952 | SH | SOLE | 11,952 | 0 | 0 | ||
| Immunomedics Inc | COM | 452907108 | 6,430 | 334,724 | SH | SOLE | 334,724 | 0 | 0 | ||
| Insmed Inc | COM PAR $.01 | 457669307 | 8,264 | 284,263 | SH | SOLE | 284,263 | 0 | 0 | ||
| Kiniksa Pharmaceuticals Ltd | COM CL A | G5269C101 | 1,223 | 67,692 | SH | SOLE | 67,692 | 0 | 0 | ||
| Madrigal Pharmaceuticals Inc | COM | 558868105 | 432 | 3,452 | SH | SOLE | 3,452 | 0 | 0 | ||
| Neurocrine Biosciences Inc | COM | 64125C109 | 2,118 | 24,040 | SH | SOLE | 24,040 | 0 | 0 | ||
| Novartis AG | SPONSORED ADR | 66987V109 | 3,834 | 45,329 | SH | SOLE | 45,329 | 0 | 0 | ||
| uniQure NV | SHS | N90064101 | 2,314 | 38,800 | SH | SOLE | 38,800 | 0 | 0 | ||
| Sage Therapeutics Inc | COM | 78667J108 | 986 | 6,200 | SH | SOLE | 6,200 | 0 | 0 | ||
| Sarepta Therapeutics Inc | COM | 803607100 | 2,535 | 21,270 | SH | SOLE | 21,270 | 0 | 0 | ||
| Stemline Therapeutics Inc | COM | 85858C107 | 4,183 | 325,526 | SH | SOLE | 325,526 | 0 | 0 | ||
| UroGen Pharma Ltd | COM | M96088105 | 4,898 | 132,589 | SH | SOLE | 132,589 | 0 | 0 | ||